We first identified breast cancer cell lines mimicking in vitro the drug-induced activation of the IFN/STAT1 signature observed in vivo, then we used these models to decipher both the upstream mechanisms and downstream consequences of this IFN/STAT1 fingerprint. Here, STAT1 is linked to breast cancer.